Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in
chemotherapy work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing. Chemoembolization kills tumor cells by blocking the
blood flow to the tumor and keeping chemotherapy drugs near the tumor.
PURPOSE: This phase I trial is studying side effects and best dose of sorafenib tosylate when
given together with chemoembolization in treating patients with unresectable liver cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania